Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Gastman

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Journal for Immunotherapy of Cancer|June 1, 2018
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0Ryan J Sullivan, Michael B Atkins, John M Kirkwood, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 9, 2019
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyDaniel G Coit, John A Thompson, Mark R Albertini, et al.
Cancer Discovery|November 12, 2021
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk MelanomaKenneth F Grossmann, Megan Othus, Sapna P Patel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 12, 2021
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021Susan M Swetter, John A Thompson, Mark R Albertini, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2016
NCCN Guidelines Insights: Melanoma, Version 3.2016Daniel G Coit, John A Thompson, Alain Algazi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 13, 2018
Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in OncologyChristopher K Bichakjian, Thomas Olencki, Sumaira Z Aasi, et al.
Journal for Immunotherapy of Cancer|November 17, 2020
Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery CommitteeBrian Gastman, Piyush K Agarwal, Adam Berger, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 6, 2020
NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019P Kumar Rao, Christopher Barker, Daniel G Coit, et al.
Journal for Immunotherapy of Cancer|October 2, 2021
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrenceCraig L Slingluff, Karl D Lewis, Robert Andtbacka, et al.
Biorxiv : the Preprint Server for Biology|December 3, 2025
Lymphotoxin-driven cancer cell eradication by tumoricidal CD8<sup>+</sup> TILHongyan Xie, Aiping Jiang, Aonkon Dey, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Journal for Immunotherapy of Cancer|June 1, 2018
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0Ryan J Sullivan, Michael B Atkins, John M Kirkwood, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 9, 2019
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyDaniel G Coit, John A Thompson, Mark R Albertini, et al.
Cancer Discovery|November 12, 2021
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk MelanomaKenneth F Grossmann, Megan Othus, Sapna P Patel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 12, 2021
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021Susan M Swetter, John A Thompson, Mark R Albertini, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 7, 2016
NCCN Guidelines Insights: Melanoma, Version 3.2016Daniel G Coit, John A Thompson, Alain Algazi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 13, 2018
Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in OncologyChristopher K Bichakjian, Thomas Olencki, Sumaira Z Aasi, et al.
Journal for Immunotherapy of Cancer|November 17, 2020
Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery CommitteeBrian Gastman, Piyush K Agarwal, Adam Berger, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 6, 2020
NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019P Kumar Rao, Christopher Barker, Daniel G Coit, et al.
Journal for Immunotherapy of Cancer|October 2, 2021
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrenceCraig L Slingluff, Karl D Lewis, Robert Andtbacka, et al.
Biorxiv : the Preprint Server for Biology|December 3, 2025
Lymphotoxin-driven cancer cell eradication by tumoricidal CD8<sup>+</sup> TILHongyan Xie, Aiping Jiang, Aonkon Dey, et al.
Pageof 7